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Liver disease: a 
ticking time bomb
Liver disease in the UK is killing more people than diabetes 
and road deaths combined; it is the fifth biggest cause of death 
in England and Wales, after heart disease, cancer, stroke and 
respiratory disease1. The rate of death in all these major causes 
of death is reducing in the UK except for one: liver disease.  A 
total of 16,087 people died from liver disease in 2008, and if the 
rate continues at its current pace, deaths from liver disease are 
1  Office for National Statistics: Health Service Quarterly, Winter 2008, No. 40 p59-60
predicted to double in the next 20 years. Despite this looming 
crisis it has to be remembered that the three main causes of liver 
disease − alcohol, obesity and blood borne infections, in particular 
hepatitis B and C – are all preventable and treatable. 
“ there can be a lack of confidence about liver disease in primary care, 
leading to a failure to both prevent 
and diagnose problems” 
People dying from liver disease die young: the average age of 
death is 59 − and this average age is falling − as compared to 
over 70 for the other major killers2. People with liver disease tend 
to be ill for 3-5 years before death. However for many the period 
of illness is longer and the social and economic cost is significant. 
A typical patient will have 5-10 hospital admissions before dying. 
Around 700 people will receive a liver transplant, and this number 
is rising. Some have calculated that the cost of liver disease could 
be as high as 1 billion by 2015. As with so many other conditions, 
health inequalities compound the problem, with socially excluded 
populations experiencing higher levels of liver disease. 
And yet there can be a lack of confidence about liver disease in 
primary care, leading to a failure to both prevent and diagnose 
problems.  One difficulty with diagnosis is that liver disease is often 
2  A joint response on behalf of liver disease clinicians and patients by British Association 
for the Study of the Liver (BASL), British Liver Trust (BLT) and British Society of Gastro-
enterology (BSG) to the White Paper ‘Equity and Excellence: Liberating the NHS’
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Editor
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@
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SMMGP is becoming increasingly concerned about the rise in liver disease in the UK and we are pleased to bring you this special 
edition on the liver. People using drugs and alcohol are at particular risk of liver disease, and in this edition of Network we aim to 
provide the knowledge to better diagnose, refer and support the treatment of this growing problem.
Liver special edition
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silent until it is very advanced. Once advanced, it is clearly best 
treated by the experts and so this can lead to a level of uncertainty 
about how to deal with the disease. This special edition of network 
will look at what primary care can do to improve prevention and 
diagnosis, and also to support people who are going through 
treatment. Jude Oben and colleagues run through the basics of 
non alcoholic fatty liver disease on page 3, and help is provided 
by Carsten Grimm when he gives some hints and tips on how to 
diagnose alcohol related liver disease on page 4. Helen’s story of 
how her GP missed her symptoms of hepatitis C is an important 
reminder about diagnosis on page 5. 
Although HCV detection rates are improving, the numbers going 
on to be treated remain low: of the 13,000 new cases of hepatitis 
C infection in the UK per year we are treating around 5,0003. Euan 
Lawson gives some practical suggestions about finding cases of 
hepatitis B and C on page 6.
Patients with hepatitis C will be familiar to many of our readers, but 
we may not always know what happens once the referral has gone 
to the specialist. Brian Thompson gives some detail on factors 
that lead to progression of liver disease for those with hepatitis 
on page 10. Treatment for hepatitis C has greatly improved in the 
3  The All Party Parliamentary Hepatology Group (2010) In the dark. An audit of hospital 
hepatitis C services across England London.
…continued from page 1
Editorial
We feel it is important to have a special edition on the liver due 
to the growing problems with liver disease and are pleased to 
have the help of guest clinical editor Euan Lawson. We hope 
to guide you through the issues of liver disease and provide 
you with the knowledge to support the prevention, diagnosis, 
referral on and the management of liver treatment in primary 
care, where so much can be done.
It has been a busy time for SMMGP, with our conference on 
13th October being a sell out − see www.smmgp.org.uk for 
presentations. One of the key messages I took from the day 
was the importance of clinicians and patients engaging with 
the new NHS Clinical Commissioning Groups and the Health 
and Wellbeing Boards, so watch out for more on this from 
SMMGP.  
We have also developed materials for the RCGP Certificate in 
the Detection, Diagnosis and Management of Hepatitis B and 
C in Primary Care which was launched in September. A two 
hour emodule is freely available at http://elearning.rcgp.org.uk 
and can be done as a standalone or in preparation for the 
Part 1 Training Day (see page 16 for more details).
We are very excited to announce the 17th National RCGP 
Conference Managing drug and alcohol problems in primary 
care will take place in Cardiff on 11th May 2012. The title of the 
conference is Going for gold: right treatment, right time, 
right place. Save the date, and watch out for more details on 
our website. 
Enjoy this issue!
Kate Halliday Editor
last decade and there continue to be advances. Graham Foster 
and Morven Cunningham give us a glimpse into the future in their 
article What’s new on the horizon for treatment of hepatitis C? on 
page 8 and Iain Brew take us through the ways in which we can 
support people going through treatment for hepatitis C in his article 
on page 12. 
“ Primary care is perfectly placed to prevent, diagnose 
and support the treatment of 
liver disease”
Primary care can play an important role in preventing the spread 
of hepatitis C and advising hepatitis C positive individuals on how 
to reduce harm to their liver if they do not wish to be treated: Dr 
Fixit Mark Hallam gives advice to a GP on how to do so on page 
13. For those working with people using drugs and alcohol, liver 
disease is an important issue; up to 50% of injecting drug users are 
positive for hepatitis C, and it is important to prevent, diagnose and 
manage the problem. Add to this the fact that up to 25% of those 
in methadone treatment are problematic drinkers4, and the risks to 
the liver get worse. A recent study found that the cause of death 
for 1 in 5 patients in methadone treatment had liver disease as an 
underlying cause5. The final ingredient of this dangerous cocktail, 
the compounding effect of health inequalities, means that we must 
be especially aware of liver disease amongst those with drug 
problems. On page 14, Steve Brinksman is Dr Fixit to a GP with 
a patient with hepatitis C who is overweight and drinking alcohol, 
and suggests that there is a lot primary care can do limit harm to 
the liver and to prepare people for treatment.
The quiet killer has also been largely silent in policy. Despite the 
fact that we are failing to tackle the increasing harms and costs of 
liver disease, it has somehow failed to appear in National Service 
frameworks, or Quality Outcome Framework (QOF) indicators. 
Following increasing pressure from organisations including the 
British Liver Trust (BLT), the British Association for the Study of the 
Liver (BASL) and the British Society of Gastroenterology (BSG) the 
Department of Health are in the process of developing a National 
Strategy for Liver Disease which will begin to bridge some of the 
current gaps in policy. Martin Lombard, National Clinical Director 
for Liver Disease who is tasked with developing the strategy 
outlines some of the issues in a briefing paper on page 11.
Primary care is perfectly placed to prevent, diagnose and support 
the treatment of liver disease and it may soon play a role in 
commissioning services. And yet myths and a lack of confidence 
can hinder primary care’s response. There can be a misconception 
that liver disease is all about alcohol use which can lead to a failure 
to diagnose. There can be a belief that there is nothing we can do 
about liver disease: and yet it is almost never too late to intervene. 
With the right support, primary care has the ability to play an 
essential role in reducing the burgeoning harm of liver disease to 
individuals, communities and society.
Kate Halliday SMMGP 
4  Gossop, M , Marsden, J   Stewart D (2001)National Treatment Outcome Research 
Study NTORs After Five Years National Addiction Centre
5  Gibson A, Randall D, Degenhardt A (2011) The increasing mortality burden of liver 
disease among opioid dependent people: cohort study.  . Addiction 2011. Postprint. 
doi:10.1111/j.1360-0443.2011.03575.x 
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Jude Oben and colleagues run through 
the basics of non alcoholic fatty liver 
disease. Read this article to improve 
your diagnostic skills! Ed
Practical 
management of 
non alcoholic 
fatty liver disease 
in primary care
Introduction
Non alcoholic fatty liver disease 
(NAFLD) is the leading cause of liver 
dysfunction in developed countries.  The 
predominant cause of NAFLD is obesity 
and its pathogenesis implicates insulin 
resistance and increased oxidant stress 
with consequent activation of fibrogenesis. 
Presently, NAFLD cannot be diagnosed 
with a single test. Given its association 
with obesity, the initial treatment is dietary 
modification and increased physical activity. 
Definition
Non alcoholic fatty liver disease (NAFLD) 
is a spectrum of liver disease ranging 
from hepatosteatosis (fatty liver), to non-
alcoholic steatohepatitis (NASH) (fat with 
inflammation), through to fibrosis and 
potentially cirrhosis and hepatocellular 
carcinoma without a history of immoderate 
alcohol use.  NAFLD patients who become 
cirrhotic usually exhibit a reduction in their 
degree of steatosis.  NASH is a more severe 
stage of NAFLD.
Prevalence
The population prevalence of NAFLD has 
been estimated at 7-35%, using alanine 
transaminase levels, ultrasound scanning or 
magnetic resonance spectroscopy (MRS), 
as diagnostic techniques, of which MRS is 
most sensitive for detecting liver fat. NAFLD 
prevalence is around 15% in Asian and 20-
30% in Western adults.  Estimates of NASH 
prevalence are at around 2.5%, making 
NASH more widespread than chronic 
hepatitis B and C, alcoholic liver disease and 
other metabolic liver diseases. The rising 
rates of obesity worldwide parallel rising 
rates of NAFLD and as such it is projected 
that within the next decade a greater number 
of patients will be transplanted for NAFLD 
than for end stage chronic hepatitis C.  
Risk factors
Risk factors associated with NAFLD are 
mainly features of the (dys) metabolic 
syndrome: obesity, type 2 diabetes, 
insulin resistance, hypertension, and 
dyslipidaemia.  Male sex and increased waist 
circumference are also well established risk 
factors.  NAFLD is primarily associated 
with increased intra-abdominal fat mass. 
NAFLD has been shown to be clustered 
within families and patterns of inter-ethnic 
variation have also been documented. It has 
recently been shown that maternal obesity 
by means of programming during neonatal 
and immediate perinatal development 
can increase susceptibility to NAFLD in 
adulthood.
Clinical features
Most patients with NAFLD are asymptomatic 
in the early stages of disease.  However, 
symptoms can include right upper 
quadrant discomfort and general fatigue. 
Hepatomegaly and right upper quadrant 
tenderness may be present on examination. 
Diagnosis
Presently, there is no single diagnostic 
test that reliably detects NAFLD.  Its 
diagnosis is dependent on identification 
of hepatic triglyceride accumulation at the 
tissue level in an obese, insulin resistant 
and dyslipidaemic patient with little or no 
alcohol history.  Diagnosis of NAFLD is 
also one largely of exclusion.  Its presence 
is confirmed in the absence of focal liver 
lesions, positive serology for hepatitis A, B 
and C, aberrant autoimmune profile, copper, 
caeruloplasmin and ferritin.
Histological classification of hepatosteatosis 
is diagnostic of NAFLD.  The majority of 
NAFLD patients have abnormal liver function 
tests.  However, elevated transaminase 
and gamma glutamyltransferase (GGT) 
levels lack sensitivity and specificity 
for NAFLD.  Furthermore, aberrant liver 
enzymes may normalise with disease 
progression.  The aspartate transaminase 
to alanine transaminase ratio is usually <1 
unlike alcoholic liver disease where it is >1. 
However, reversal of the AST/ALT ratio to >1 
implies advanced fibrosis in NAFLD.
Serum albumin and bilirubin remain within 
physiological ranges in NAFLD patients. 
However, these levels become perturbed 
with disease progression to cirrhosis.  A low 
level inflammatory state exists in obesity 
and NAFLD which is reflected by increased 
ferritin levels in the presence of normal iron 
indices.   Raised anti-smooth muscle and 
anti-nuclear antibodies, seen in up to 25% 
of NAFLD patients, are indicative of more 
severe inflammation and injury.  
Ultrasonography is a simple, cost effective 
and non-invasive technique used to detect 
hepatosteatosis.  It has a sensitivity of 
66-100% for a fat content >33%.  CT and 
MRI have around the same sensitivity and 
specificity as ultrasonography although 
more expensive.  MRS is the most sensitive 
imaging modality, detecting hepatosteatosis 
at around 5%.  
Transient elastography (Fibroscan) is an 
alternative ultrasound imaging modality.  It 
provides information on liver stiffness which 
correlating with hepatic fibrosis.  However, 
it is technically difficult to use in obese 
patients.  
Liver biopsy is the preferred diagnostic 
technique, although invasive.  Skelley et 
al. reported that, of 354 patients being 
investigated for abnormal liver function tests 
with negative liver serology, 34% required 
revision of diagnosis post biopsy.  
Treatment
There is presently no single therapeutic 
intervention.  NAFLD is largely the 
consequence of obesity, malnutrition and 
sedentary behaviour and thus primary 
prevention are lifestyle modifications. 
Exercise improves biochemical and 
histological parameters by reducing 
visceral fat, enhancing insulin sensitivity 
and lipid oxidation. However, the risk of 
disease progression and cardiovascular 
co-morbidity may warrant pharmacological 
intervention.  
Controlled weight reduction of 5-10% of 
initial body mass improves or normalises 
liver enzymes, reduces hepatosteatosis, 
inflammation and fibrosis.  Rapid weight 
loss has been correlated with accelerated 
disease progression in NAFLD patients. 
Weight loss surgery (bariatric surgery) in a 
cohort of NASH patients has been shown to 
improve hepatosteatosis, necroinflammatory 
changes and fibrosis.  Similarly, a recent 
prospective study reported improvement of 
ballooning and steatosis post-operatively at 
1 and 5 years in NASH patients.  
Anti-obesity pharmacotherapy includes 
orlistat, sirbutamine and rimonabant.  Orlistat 
is a gastrointestinal lipase inhibitor that aids 
weight loss and reduces plasma FFAs in 
NAFLD.  It is thought to be most efficacious 
as an adjunct to dietary intervention.   Anti-
oxidants and hepato-protectants may also 
have a therapeutic role.  Cytoprotective 
agents include ursodeoxycholic acid 
(UDCA), s-adenosylmethionine, betaine, 
pentoxifylline and vitamin E.  
Summary
The term NAFLD encompasses a spectrum 
of histological features from steatosis to 
cirrhosis. It is the most common cause of 
chronic liver disease worldwide, rising in 
tandem with obesity and type 2 diabetes. 
Insulin resistance and oxidative stress are 
important in disease progression.  There 
is presently no single diagnostic test for 
NAFLD, although, emerging modalities with 
greater sensitivity and specificity may aid 
future diagnosis, staging and management. 
Similarly, there are no approved treatments 
of NAFLD.  In the majority of cases, 
treatment strategies commence with 
lifestyle modifications and may include 
pharmacotherapy in the form of insulin 
sensitizers, cholesterol lowering agents, 
anti-obesity and anti-oxidant agents.  
Mouralidarane A, Soeda J, Oben JA,  
University College London, Centre 
for Hepatology, Royal Free Hospital, 
London; Guy’s and St Thomas’ Hospital, 
London
A full list of references is available at  
www.smmgp.org.uk
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Managing alcohol-related liver disease (ALD) is a difficult 
clinical situation which many doctors struggle with. Carsten 
Grimm gives an overview of the current guidelines and 
makes the case for more cooperation between primary and 
secondary care. Ed
Alcohol and the liver
One of my pet hates is the invisible line that crosses our healthcare 
system: it’s the one between primary and secondary care, or 
generalists and specialists. I am a fan of general practice, and 
equally admire the knowledge and dedication of consultants.
General practice requires autonomy to make decisions and 
judgments, otherwise it will not work as a gatekeeper in the 
healthcare system. Guidelines help us to make decisions, but do 
not replace our independent thinking. Not every chest pain will get 
referred to the hospital and not every abnormal liver function test 
(LFT) will get seen by a hepatologist. This is not bad medicine; this 
is good practice as long as doctors are competent, well trained 
and experienced.
“ General practice requires autonomy to make decisions 
and judgments, otherwise it will 
not work as a gatekeeper in the 
healthcare system” 
The National Institute for Health and Clinical Excellence (NICE) has 
published two clinical guidelines about alcohol misuse within the 
last year1 2. They are comprehensive and sticking to them will make 
any practitioner do the right thing in the vast majority of cases. 
However, there are some parts of the guidelines that require us to 
think about how and why we need to implement them very carefully.
So what does NICE recommend regarding diagnosis of alcohol 
use disorders and liver disease?
1 Simple biological measures such as liver function 
tests are poor indicators of the presence of harmful or 
dependent drinking.
So let’s not use them any more to determine how bad a drinking 
problem is. This is much better done by using either screening 
questionnaires like AUDIT (Alcohol Use Disorders Identification 
Test) and SADQ, (Severity of Alcohol Dependence Questionnaire) 
or even better by an expert assessment. 
2 Consider blood tests to help identify physical health 
needs, but do not use blood tests routinely for the 
identification and diagnosis of alcohol use disorders.
What does this mean in practice? Anyone who is classified as a 
harmful, or dependent drinker should have LFTs done routinely 
as part of their assessment because the risk of developing liver 
disease is 13 times higher in harmful drinkers as compared to low 
risk drinkers3, so it makes a lot of sense to have a closer look at 
the liver. In some ways, it might be even more important to check 
LFTs for harmful drinkers than for dependent individuals as we 
have a fairly good idea what we do next for this group and how to 
1 National Institute for Health and Clinical Excellence (2010) Alcohol use disorders: physi-
cal complications Clinical Guideline 100
2 National Institute for Health and Clinical Excellence (2011) Alcohol dependence and 
harmful use Clinical Guideline 115
3 HM Government (2007) Safe. Sensible. Social: the next steps in the national alcohol 
strategy
do it: brief intervention, which works in one in eight patients 4. So 
by simply advising individuals to reduce their alcohol intake in a 
structured way we can reduce the risk considerably. Unlike harmful 
drinkers, dependent drinkers are more difficult to treat and need 
more interventions and considerably more resources.
We must not forget that we are only talking about risk and that even 
a lower risk drinker can develop serious problems with the liver, 
though it is far less likely. This is similar to cardiovascular disease 
risk assessment; even a low cardiac risk score does not rule out 
the risk of having a heart attack. So we still have to be aware that 
it might be necessary to investigate the liver in someone who does 
not drink too much. This is also due to the fact that some other 
liver diseases might be adversely affected by consuming even a 
low amount of alcohol. For example, someone who has chronic 
hepatitis C and continues to drink to hazardous levels might run a 
high risk of developing liver failure very soon. 
3 Exclude alternative causes of liver disease in people 
with a history of harmful or hazardous drinking who have 
abnormal liver blood test results. 
The good news is that this refers to a one-off array of blood tests 
to exclude viral hepatitis and autoimmune diseases. The bad news 
is that there is no national guideline that defines what exactly we 
need to test for. Which brings me to the next recommendation:
4 Refer people to a specialist experienced in the 
management of alcohol-related liver disease to confirm a 
clinical diagnosis of alcohol-related liver disease. 
This is the one that makes me feel uneasy: taking all the above into 
account, can we fulfill this without sending every single person with 
slightly abnormal LFTs who is drinking too much to a specialist? 
This is what I would recommend: liaise with your local hepatology 
department to establish what you want to do locally by approaching 
the newly established Clinical Commissioning Groups. I would be 
surprised to find any specialist who is keen to see all individuals 
with abnormal LFTs and a history of drinking too much in their 
clinics. We should be able to train general practitioners to a level 
that they are indeed competent to exclude other causes and make 
the diagnosis of alcohol related liver disease. 
As for substance misuse specialist services, we have a well-trained, 
highly motivated and geographically wide spread workforce in 
substance misuse. As alcohol treatment services are tendered out, 
should we not make it part of their work to do exactly that: diagnose 
and manage alcohol-related liver disease?
Which brings me back to my pet hate: the division between 
primary and secondary care. In order to maintain good access and 
manageable workloads in secondary care, we need to do as much 
as we can in primary care. Working with vulnerable and excluded 
groups gives me a sense of the poor attendance rate that people 
with problematic alcohol use have with specialists. There are many 
reasons why this might be; seeing a consultant usually means an 
appointment in a less-than-friendly, large and busy environment 
(hospital) to see someone who does not know you.
I think the diagnosis and large parts of the management of alcohol-
related liver disease can and should be part of general practice. 
Our two colleges, the Royal College of General Practitioners and 
the Royal College of Physicians need to work together to achieve 
this to prevent an unsustainable increase in referrals.
Carsten Grimm RCGP Alcohol Certificate Clinical Lead 
4 Babor et al (2003)Alcohol: No Ordinary Commodity - Research and Public Policy; Mesa 
Grande: a methodological analysis of clinical trials of treatments for alcohol use disor-
ders. Addiction 2002 Mar;97(3):265-77
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Helen, 48, contacted the British Liver Trust earlier this year 
exasperated by the lack of care she was receiving from her 
local GP, reminding us that chronic hepatitis C can present 
in almost any way and we all need to think about it! Helen 
is unsure how she contracted hepatitis C. Here is her story, 
followed by a piece by Euan Lawson on how to improve 
diagnosis of hepatitis C. Ed.
Living with HCV
I started going to my GP in May 2006 after experiencing bad night 
sweats and disturbed sleeping patterns. I was waking up in the 
early hours of the morning, wide awake and raring to go; my legs 
would be itchy at night, so much so that I kept dousing my cats with 
flea treatment until they started avoiding me!
The GP immediately said “menopause” – I was 43. 
Surprised by the initial assumption, I mentioned that none of my 
family had had an early menopause and he just shrugged and said 
it happens - he said the itchy legs were dry skin until I showed him 
what soft skin I have and then he shrugged. Even when I started 
to lose weight for no reason and I started to freak out my GP was 
really calm about it. I went from 55kg to 49kg in about 30 days and 
would wake up in the morning and wonder where the rest of me 
had gone. 
Throughout this time I was also being treated by a consultant 
for rheumatoid arthritis (RA), which was diagnosed in 2003. The 
joint pain I had started to experience from 2009 was getting 
progressively worse and was affecting my hands, shoulders, 
neck and leg joints.  The RA consultant was brilliant but he told 
me he couldn’t reconcile the amount of joint damage he could 
see with the amount of pain I reported experiencing. He advised 
me to go back to my GP because he thought something else was 
going on.
After returning again to my GP, I was sent for blood tests and 
was diagnosed hepatitis C positive. I was referred and I went to 
the consultant, who was very relaxed about it and explained the 
treatment options available to me. I told her I was studying for a 
degree and working full time and I didn’t want to do treatment if I 
didn’t have to and she said no problem, come back again in a year. 
I did have an ultrasound and it came back clear so I forgot about 
the hepatitis C.   It never occurred to me to look it up, or connect 
my symptoms with hepatitis C, because nobody suggested they 
could be connected. 
However in May 2010 I started to get diarrhoea up to six times a 
day and sometimes it would occur as I was eating. Certain foods 
would make my digestive system spring into life, including anything 
sugary or with vitamin C, so I cut out fruit. I noticed all the tiny little 
bruises on my legs, how dry everything was, for instance my eyes 
were a nightmare. I wanted to pee all the time and I would eat my 
dinner, yet be ravenous within five minutes. This was when I wasn’t 
off food and throwing up of course.
I had become slightly erratic in my personality and I would be 
very chatty with strangers including shop assistants and people 
in queues. There was a slight air of mania to it and people could 
sense it; I could see them hoping I would go away soon. It got 
to the point where I didn’t want to go out any more, even when I 
had made arrangements with people I would spend all my time 
trying to find a reason not to go.  I had also developed nervous 
system problems where I couldn’t relax my face properly and I was 
holding my shoulder in a strange way that caused neck pain. It 
got to the point where the pain in my jaw was so bad I couldn’t 
bite an apple. 
“ I had become slightly erratic in my personality 
and I would be very chatty 
with strangers including 
shop assistants and people 
in queues”
I’m now five months in to a relatively symptom free treatment on 
a trial drug with the research team under Dr Agarwal at Kings. 
Hopefully I will be stopping at week 24 but I won’t know until then. 
So here I am. Apart from the fact that I’m tired and my eyebrows 
seem to be packing their bags and moving, the treatment has 
at least given me the opportunity to follow a new career – I am 
thinking of phoning Maybelline or L’Oreal and offering my services 
as an eyelash model! Helen is currently undergoing a clinical trial 
at King’s College Hospital in London. She is genotype 1a and the 
virus was undetected at week two.
Helen’s case – going beyond the usual risk factors
Helen’s case illustrates the wide range of symptoms that people 
with chronic hepatitis C (HCV) infection may experience and one 
of the key areas for GPs, as emphasised by Helen’s article, is the 
need for those in primary care to have a high awareness of the 
potential for a non-specific presentation.
For many the perception remains that chronic viral hepatitis will 
sit relatively quiet and dormant but there is a significant impact on 
individuals. An important paper by Foster back in 1998 investigated 
quality of life in people with HCV infection1. They used the short 
form 36 (SF36) questionnaire in 72 patients who were known to 
have chronic HCV infection but who were not undergoing active 
treatment. This is very similar to the position that Helen was in when 
she decided to defer treatment. The study showed, quite clearly, 
that patients with chronic hepatitis C tend to be poly-symptomatic 
and have significant reductions in their quality of life across all 
areas. The study also showed that this was not related to severity 
of liver disease. This reduction in quality of life also persisted 
when injecting drug users (who were more severely affected) were 
removed from the analysis.
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Helen’s case is entirely typical of the experience of many people 
with chronic hepatitis C. It is not uncommon for people to recount 
a long history of non-specific symptoms but particularly tiredness, 
…continued overleaf
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…continued from previous page
odd skin conditions, changes and low mood and odd aches and 
pains, a delayed diagnosis and a realisation, after successful 
treatment, of how much chronic hepatitis C infection had impacted 
on their life. 
It is clearly important that everyone in primary care has a solid 
understanding of the risk factors associated with viral hepatitis 
B and C but it is also important that we think of it when people 
present with an odd collection of symptoms. It may arguably be 
worth checking HBV, HCV and HIV alongside liver function tests in 
those patients presenting with tiredness. Helen is not sure how she 
contracted HCV and her case highlights nicely the importance of 
good quality long-term relationships with patients. We need to have 
a better appreciation of the range of presentations and the impact 
on quality of life of a condition such as chronic HCV infection.
Helen’s story, with thanks to Helen and the British Liver Trust
1. Foster GR, Goldin RD, Thomas HC. (1998) Chronic hepatitis C virus infection causes a 
significant reduction in quality of life in the absence of cirrhosis. . 1998 Jan.;27(1):209–
212. 
Euan Lawson gives some practical suggestions about 
finding cases of hepatitis B and C. Ed
Suggestions to find and 
manage hepatitis B 
and C in your practice
Run an audit in your practice
Almost 90% of the newly diagnosed people with hepatitis C (HCV) 
infections in the UK are in people who are currently injecting or 
have injected drugs in the past. The Health Protection Agency 
estimates 44% are in current injectors, 43% in past injectors, 5.6% 
in South Asian ‘never injectors’ and 7.3% in white/ other ethnicity 
‘never injectors’. Over 90% of cases of hepatitis B (HBV) infection 
are imported, particularly from Africa, Brazil, Peru, China and other 
South East Asia regions. An example audit would run a search 
for all individuals coded with past or current drug use and look to 
see if they have their HCV and HBV status coded and if HCV that 
they have had a PCR test. Those that don’t could be invited in or 
have a screen message added to their computer notes suggesting 
they should be offered testing and hepatitis B immunisation 
opportunistically.
Alternatively, it should be possible to identify those with a diagnosis 
of chronic hepatitis B or C in the practice and find out if they have 
been offered referral in the past 2 years and support. Have they 
had a medical review in the past year? If not offer one and discuss 
new treatments and the reason for early treatment.
Audit can be a powerful tool to drive change in practice and has 
the potential to find cases as well as improve management of those 
who have been diagnosed.
Create a chronic hepatitis B and C register
Ensure you know who is being treated for hepatitis B and C in the 
practice. This could also be tied in to the audit work as cases are 
found and given appropriate Read Codes. Offer this group regular 
check-ups and support them through their treatment. There is 
much primary care can do to improve and build on care for those 
with chronic hepatitis infections.
Signs and symptoms
Have a low threshold for checking liver function tests (LFTs) 
in individuals with vague or non-specific symptoms. Anyone 
with abnormal LFTs should have their HBV/HCV status checked 
immediately - don’t wait for further tests. The evidence suggests 
this is more cost-effective that a wait-and-see policy where LFTs 
are repeated1. Just test them. 
Education, education, education
Develop your skills and knowledge around hepatitis B and C. 
Considering attending a course such as the RCGP Part 1 course. 
Run a small session for practice staff or encourage them to do the 
emodule so that all practice staff have an improved awareness. It 
may also be useful to build links with the local hepatology service 
– be familiar with the local referral criteria and many will have nurse 
specialists who can help support patients in the community.
Euan Lawson Clinical Lead for the RCGP Certificate in the 
Detection, Diagnosis and Management of Hepatitis B and C in 
Primary Care 
1. Arnold DT, Bentham LM, Jacob RP, Lilford RJ, Girling AJ.(2011) Should patients with 
abnormal liver function tests in primary care be tested for chronic viral hepatitis: cost 
minimisation analysis based on a comprehensively tested cohort.  2011;12:9. 
Harm 
reduction and 
the liver
Are we looking after people’s liver health 
as well as we could be? 
Chris Ford explains how we can take a 
harm reduction approach to the liver on 
our website www.smmgp.org.uk
Stages of liver disease
 Fatty Liver Liver fibrosis Cirrhosis
  
 Deposits of fat Scar tissue forms. Scar tissue makes
 causes liver More liver cell liver hard and unable
 enlargement. injury occurs. to work properly.
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Euan Lawson and discusses the ins and outs of hepatitis A 
and B immunisations. Ed
Some thoughts on 
managing hepatitis B 
and A immunisations
The Department of Health gives clear advice in Immunisation 
against infectious disease on the groups that should be vaccinated 
against hepatitis B1. Known popularly as the ‘Green Book’ this gives 
detailed advice on immunisation schedules but it can be easy to 
feel that the chaotic circumstances found in the real world don’t fit.
The standard regime recommended for hepatitis B is the 
‘accelerated’ schedule where immunisations are given at 0, 1 
and 2 months. Those at continued risk should be given at fourth 
dose at 12 months. The alternative of giving vaccines at 0, 1 and 
6 months should only be used where there are no concerns about 
compliance and there is no need for immediate protection. There is 
a slightly reduced immunogenicity with the accelerated schedule 
but this is offset by a much improved compliance – particularly in 
groups such as injecting drug users where this can be a factor.
 
Partial immunisation
How do we manage people who have had partial courses of 
immunisation? This feels common in clinical practice and is 
unsurprising given that the populations that are most at risk often 
have fragmentary and inconsistent contacts with primary health 
care. 
It is tempting to test for antibodies in all those who have had partial 
courses to assess whether or not they need further immunisation. 
However, the situation is not clear cut and the Green Book advises 
that we should only be testing for seroconversion in certain groups 
- such as healthcare professionals. It isn’t usually appropriate to 
test other risk groups. 
Despite the recommendations there may be some circumstances 
where anti-HBs has been tested. It is important not to interpret this 
test in isolation. Remember that it is possible for someone to be 
infected with hepatitis B and then go on to be a chronic carrier 
- they won’t have any anti-HBs but they will be HBsAg positive 
and anti-HBc positive. If you test solely for anti-HBs then you may 
have just missed a case of chronic hepatitis B. It’s good practice 
to ensure that acute and chronic hepatitis B infection have been 
excluded.
The overall aim of the DH’s immunisation programme is to ‘provide a 
minimum of three doses of hepatitis B vaccine to individuals at high 
risk of exposure to the vaccine or complications of the disease’. 
This is the key objective to bear in mind and, alongside the clinical 
history, will mean a pragmatic plan can be fleshed out to manage 
normal immunocompetent adults who have had a partial course of 
HBV immunisation. Aim to ensure three doses have been given and 
those individuals can be regarded as having received a course of 
primary immunisation. Re-starting from scratch with every single 
person who has a partial course is likely to be over-cautious but 
may be necessary if there is no clear history of immunisation at all.
“ There can be concerns from practitioners about single 
or combined vaccines - there 
isn’t a ‘better’ vaccine but 
they do have slightly different 
characteristics”
After primary immunisation
The full length of protection offered by hepatitis B vaccine isn’t 
clear. It is known that vaccine-induced anti-HBs antibodies will 
go down over time. However, there is evidence that this doesn’t 
give the full story in terms of someone’s protection – some ‘immune 
memory’ is thought to persist. Currently, a one-off booster around 
5 years after primary immunisation is recommended. Antibody 
testing isn’t recommended before or after this booster.
Hepatitis A immunisation
Hepatitis A immunisation is recommended in a number of groups 
including travellers to areas with high or intermediate prevalence. 
It is recommended for those with chronic liver disease of any cause 
– including chronic hepatitis B and hepatitis C infection. This is 
due to concern that it may cause a more serious illness in these 
individuals. It is also recommended for men who have sex with 
men, injecting drug users and the homeless. 
The vaccine is available on its own or in combination with hepatitis 
B. The monovalent vaccine has a bigger dose and if very rapid 
protection is required then a single dose of the monovalent vaccine 
is better and is all that is needed to provide primary immunisation. 
A booster is recommended at 6 to 12 months and, at present, a 
further booster at 20 years is also recommended. The combined 
vaccine primary schedule will work well for those who need 
immunisation against both hepatitis A and B and the schedule for 
Twinrix® consists of three vaccines at 0, 1 and 6 months. There can 
be concerns from practitioners about single or combined vaccines 
- there isn’t a ‘better’ vaccine but they do have slightly different 
characteristics and the choice should be tailored to the individual’s 
clinical circumstances.
For full information on groups to immunise then download the most 
current version of at the Department of Health website (tinyurl.com/
DHGreenBook).
Euan Lawson Clinical Lead for the RCGP Certificate in the 
Detection, Diagnosis and Management of Hepatitis B and C in 
Primary Care 
1. Department of Health. (2006). 1st ed. London: The Stationery Office; 2006. 
Immunisatio
n against
infectious di
sease
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Graham Foster and Morven Cunningham give us a glimpse into 
the future of hepatitis C treatment: it looks like things may be 
about to get better. Ed  
What’s new on the 
horizon for treatment 
of hepatitis C?
These are exciting times for those involved in treatment of patients 
with chronic hepatitis C infection (HCV), as the first radical new 
therapies for almost two decades have recently been approved in 
the USA. Current standard treatment, involving weekly injections 
of pegylated interferon alpha and twice daily oral ribavirin for 48 
weeks results in a sustained virological response (SVR, defined 
as undetectable HCV RNA 24 weeks after treatment, which 
probably equates to a cure) in less than 50% of patients infected 
with genotype 1 HCV1 2. Treatment is often poorly tolerated, with 
unpleasant side effects including flu-like symptoms, fatigue, 
mood disturbance, anaemia, dry skin and alopecia. Without 
improvements in treatment uptake and success the burden of 
chronic liver disease due to HCV in England is set to rise3, hence 
the pressing need for new treatments with better efficacy and 
tolerability.
New antiviral strategies in drug development
A number of different approaches are being taken to develop 
new drugs to treat chronic HCV. These include:
■	 Direct acting antiviral agents (DAAs), which 
specifically inhibit key viral proteins
■	 Drugs targeting host proteins which are required for 
viral replication
■	 Modifications of interferon and ribavirin to increase 
efficacy and reduce side effects
1  Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. (2002) 
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 
2002 Sep 26;347(13):975-82.
2  Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et 
al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus 
ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001 Sep 
22;358(9286):958-65.
3  Health Protection Agency Centre for Infections (2009) Hepatitis C in the UK 2009. 
London 
Other strategies which show promise, but are currently at less 
advanced stages of development, include viral entry inhibitors 
and therapeutic vaccines.
Direct-acting antiviral agents
Replication of HCV is dependent on a number of viral non-
structural proteins, so these represent attractive targets for 
antiviral drug development. Drugs which inhibit the viral NS3/4A 
serine protease, the viral NS5B polymerase and agents which 
bind to the NS5A viral replication complex have all shown 
impressive anti-viral activity in vitro and in vivo. However, a 
significant downside to these agents is the potential for viral 
mutations to occur at the drug target site, conferring reduced 
susceptibility to the drug. Rapid emergence of drug-resistant 
viral variants occurs when most classes of DAA are given as 
monotherapy. Adding interferon and ribavirin suppresses the 
emergence of resistant variants, so for the time being at least 
these agents will need to be given together with current standard 
therapy. 
Telaprevir and boceprevir are NS3/4A serine protease inhibitors 
which have recently been approved by the Food and Drug 
Administration in the United States and at the time of writing, 
approval in Europe is expected imminently. Several more 
protease inhibitors are in phase 2 and 3 clinical trials. In phase 
3 trials, addition of either telaprevir or boceprevir to standard 
therapy substantially improved treatment response for patients 
with genotype 1 HCV, with SVR rates of over 70%. Up to two 
thirds of treatment-naïve patients showed an early response 
to therapy, and in these patients the total duration of treatment 
could be shortened to 24-28 weeks with no adverse effect on 
SVR4 5. In patients who previously failed to clear the virus after 
a course of standard therapy, retreatment with addition of a 
protease inhibitor resulted in SVR in 66% (compared to 17-21% 
in patients retreated with standard therapy alone)6 7. Notable side 
effects associated with these agents include rash (particularly 
with telaprevir, which can be severe), anaemia (particularly with 
boceprevir) and gastrointestinal disturbance. Patients who failed 
treatment with therapy containing a protease inhibitor frequently 
harboured drug-resistant viral variants. Although these variants 
declined over time after treatment, being replaced by wild-type 
virus8, whether this will compromise future treatment options for 
these patients is currently unknown.
Drugs targeting the NS5B RNA polymerase can be divided 
into nucleoside and non-nucleoside inhibitors. Nucleoside 
analogues, such as RG7128, effectively act as polymerase 
chain terminators. Whilst they show lower antiviral potency than 
protease inhibitors, they have other distinct advantages. They 
appear less susceptible to development of drug resistant viral 
variants than other DAAs, and they show similar antiviral activity 
4  Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al.(2011) 
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 
31;364(13):1195-206.
5  Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et 
al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J 
Med. 2011 Jun 23;364(25):2405-16.
6  Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. (2011) Telaprevir for 
retreatment of HCV infection. N Engl J Med. 2011 Jun 23;364(25):2417-28.
7  Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. (2011) 
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011 
Mar 31;364(13):1207-17.
8  Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang E, Spanks J, et al. Evolution 
of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Journal of 
Hepatology. 2011;54(S1):S4.
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against a range of viral genotypes, not just genotype 19. Non-
nucleoside analogues, such as filibuvir, inhibit polymerase 
activity by binding to enzyme active sites and thus act as non-
nucleoside inhibitors. Antiviral activity in short term monotherapy 
studies is comparable to nucleoside inhibitors, but, like protease 
inhibitors, efficacy as monotherapy is limited by rapid emergence 
of antiviral resistance, and poor efficacy against genotypes other 
than genotype 110. However, as part of combination therapy these 
agents may provide a further valuable option for many patients.
The precise function of the viral NS5A protein is unknown, but it is 
essential for viral replication and therefore presents another target 
for DAAs. The NS5A inhibitor BMS-790052 showed impressive 
antiviral potency  and  in dose-finding studies, but also rapid 
emergence of drug-resistant variants 11. These variants remained 
sensitive to interferon, protease and polymerase inhibitors, so 
again NS5A inhibitors are promising agents in the armament of 
antiviral combination therapy.
Inhibition of host targets
The host protein cyclophilin A is required for HCV replication. 
DEB025 (alisporivir) is a cyclophilin inhibitor which has shown 
potent anti-HCV activity alone, with additive effects when 
combined with interferon and ribavirin. Specific advantages 
are the high barrier to development of antiviral resistance, and 
efficacy against genotypes 2, 3 and 4 as well as genotype 112. 
Trials of alisporivir with interferon and ribavirin for treatment-naïve 
and treatment-experienced genotype 1 patients are currently 
in progress. Alisporivir is also being investigated in interferon- 
and/or ribavirin-free regimens in patients with genotype 2 and 3 
infection and the results are eagerly awaited. 
Improving tolerability of current therapy
Interferon lambda has similar intracellular antiviral effects to 
interferon alpha, but affects fewer cell types due to differences in 
receptor distribution. Phase 1 studies support the hope that this 
may translate to equivalent antiviral efficacy with a reduced side 
effect profile13, and further clinical trials comparing pegylated 
interferons alpha and lambda are underway.
Ribavirin is associated with anaemia, often managed by ribavirin 
dose reduction, which could compromise achievement of SVR. 
Taribavirin is an oral prodrug of ribavirin which is not concentrated 
in erythrocytes. A comparison of weight-based taribavirin with 
ribavirin did show less anaemia, but no improvement in SVR 
9  Le Pogam S, Seshaadri A, Ewing A, Kang H, Kosaka A, Yan JM, et al. RG7128 alone or 
in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus 
(HCV) Replication and selection of resistant variants in HCV-infected patients. J Infect 
Dis.  Nov 15;202(10):1510-9.
10  Wagner F, Thompson R, Kantaridis C, Simpson P, Troke PJ, Jagannatha S, et al.(2011) 
Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-in-
fected patients. Hepatology. 2011 Jul;54(1):50-9.
11  Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury TC, et al. (2011) Multiple 
ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients 
infected with hepatitis C virus genotype 1. Hepatology. 2011 Aug 11.
12  Flisiak R, Feinman SV, Jablkowski M, Horban A, Kryczka W, Pawlowska M, et al. (2009) 
The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces 
viral load in treatment-naive hepatitis C patients. Hepatology. 2009 May;49(5):1460-8.
13  Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, et al. (2010) Phase 1b 
study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic 
genotype 1 hepatitis C virus infection. Hepatology. 2010 Sep;52(3):822-32.
rates amongst those receiving taribavirin14. Whether there is a 
role for taribavirin in future combination therapy is not yet clear. 
It may perhaps prove useful in combination with DAAs which are 
themselves associated with anaemia, or in patients at particular 
risk of this side effect (such as those with renal impairment).
“ With the gathering pace of drug development, the goal of 
combination oral therapy which 
dispenses with the need for 
interferon may not be too far 
over the horizon” 
Combination therapy for HCV
Following the success of combination therapy using a number 
of drugs with varying resistance profiles in treatment of HIV 
infection, this strategy is likely to be employed in HCV therapy. 
Unlike HIV, HCV does not establish latency and so should be 
inherently curable. The ideal drug combinations, number of 
agents and duration of therapy remain to be established, and 
in the short term therapies will most likely comprise one or two 
DAAs together with interferon and ribavirin. With the gathering 
pace of drug development, the goal of combination oral therapy 
which dispenses with the need for interferon may not be too far 
over the horizon. 
Morven Cunningham, NIHR Doctoral Research Fellow, 
Queen Mary, University of London
m.e.cunningham@qmul.ac.uk
Professor Graham R. Foster, Professor of Hepatology, Barts 
and The London School of Medicine and Dentistry, Queen 
Mary, University of London
g.r.foster@qmul.ac.uk
14  Poordad F, Lawitz E, Shiffman ML, Hassanein T, Muir AJ, Bacon BR, et al.(2010) 
Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive 
patients with genotype 1 chronic hepatitis C. Hepatology. 2010 Oct;52(4):1208-15.
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Brian Thompson gives some detail on factors that lead to 
progression of liver disease for those with hepatitis. Ed
Viral hepatitis and liver 
disease – individual 
outcomes
Introduction
The UK Health Protection Agency has estimated that almost 6000 
individuals with hepatitis C virus (HCV) currently have cirrhosis, and 
up to 1500 have either end-stage liver disease or hepatocellular 
carcinoma (HCC). These figures are predicted to rise dramatically 
in the next three decades. Equivalent data for hepatitis B virus (HBV) 
are not yet available, but the prevalence of infection in populations 
from high risk areas, such as Sub-Saharan Africa and Asia is rising, 
and HBV related liver disease is a common presentation in many 
secondary care clinics. Chronic infection with hepatitis viruses is 
therefore a major burden on the NHS. 
Mechanisms of liver damage 
The mechanisms by which hepatotropic viruses lead to liver injury 
remain unclear. Most studies have concluded that cell mediated 
immune responses to viral infection is the principle mechanism of 
liver damage. This is consistent with the observation that HBV is 
associated with minimal liver damage in the early ‘immune tolerant 
phase’ of infection, despite very high levels of viral replication. HBV 
and HCV can, however, cause severe disease in individuals with 
impaired immune responses, including those with co-existing HIV 
infection and following liver transplantation, and it is likely that both 
viruses are capable of exerting a direct cytopathic effect. 
In most circumstances, HBV and HCV infection is associated 
with histological evidence of necroinflammatory change in the 
liver. Each virus is associated with distinct pathological features, 
suggestive of virus-specific mechanisms of injury. No consistent 
relationship has been demonstrated between necroinflammation 
and disease outcomes, but several studies have shown a correlation 
between median elevations in ALT, which is a surrogate marker of 
inflammatory damage to hepatocytes, and disease progression1. 
Whatever the driver, the key underlying lesion in disease 
progression is liver fibrosis. The rate of fibrosis progression, as 
assessed either by prospective grading on sequential histological 
assessment, or estimates based on estimated time from infection to 
the development of cirrhosis, is the index of disease progression. 
Cohort studies suggest that individuals with severe liver fibrosis 
secondary to hepatitis C may progress more quickly than those 
with fibrosis of other aetiologies2. HCC is a particularly important 
complication of HCV infection. The 5-year cumulative incidence of 
HCC in HCV-infected individuals is 17% in Western countries and 
30% in Japan. HBV infection carries a similar high risk of HCC. As 
a comparator, the five-year cumulative incidence of HCC is 8% in 
alcoholic cirrhosis and 4% in cirrhosis of auto-immune aetiology3. 
1 Williams M, Lang-Lenton M on behalf of the Trent Group (2010). Progression of initially 
mild hepatic fibrosis in patients with chronic hepatitis C infection. Journal of Viral 
Hepatitis; 18: 17-22.
2 Lawson A, Hagan S, Rye K et al (2007). The natural history of hepatitis C with severe 
hepatic fibrosis. Journal of Hepatology; 47: 37–45. 
3 Thomson BJ (2009). Hepatitis C virus: the growing challenge. British Medical Bulletin; 
89: 153–167.
What determines the outcome of infection in individuals?
It is clear that the outcome of chronic hepatitis infection is highly 
variable. But what factors determine whether an individual with 
HBV or HCV viraemia develops liver disease and how quickly do 
they do so? Demographic, host and environmental factors clearly 
modulate outcomes of hepatitis virus infection and consideration of 
these factors should inform our strategy of engagement. 
Demographic factors
The most informative studies of the influence of age and gender 
are based on well characterised cohorts of mothers infected with 
HCV by contaminated anti-D in Ireland and Germany and a cohort 
of plasma donors infected in Austria456. These studies share the 
invaluable advantage of accurate identification of the time of 
infection, but are otherwise strikingly different. Only 2% of the Irish 
cohort had developed cirrhosis after 17 years of follow up and 
rates were similar in the German group after 25 years. In contrast, 
34% of the Austrian cohort had severe fibrosis and 15% end stage 
liver disease or HCC at 31 years of follow up. 
What are the reasons for such diversity? 
The two most obvious differences are that: i) recipients of anti-D 
were female, while plasma donors were predominantly male and 
ii) the plasma donor cohort was older at the point of analysis. 
Other studies have confirmed that male gender and older age are 
predictive of a poor outcome in both HCV and HBV infection. Age 
in particular is consistently identified as a dominant risk factor for 
disease progression. This is not only for the obvious reasons that 
older individuals are likely to have been infected for longer, but 
because disease appears to accelerate with age. Retrospective 
analysis of a large French HCV cohort found that patients infected 
at age 20 took 44 years to develop cirrhosis, whereas those 
infected over the age of 50 progressed to cirrhosis in only 12 
years7. Prospective studies have confirmed the non-linear nature 
of fibrosis progression. The impact of age and associated liver 
disease is equally striking in response to current antiviral therapies. 
Men aged 30 infected with HCV genotype 1 and no underlying liver 
disease had a sustained response to therapy of >70%, whereas 
males aged 50 with cirrhosis had a response rate of <10%8. 
These observations provide a compelling argument for the early 
identification and treatment of chronic hepatitis C virus infection.   
Alcohol 
A strong consensus has emerged that alcohol consumption of 
>30g/day is a major co-factor in hepatitis disease progression. This 
is particularly important in populations of intravenous drug users, 
who are at greatest risk of the acquisition of HCV, and in whom 
excess alcohol consumption is common. The Dionysus study, a 
large prospective community based study in Northern Italy, has 
demonstrated that ethanol intake of more than 30g/day is the 
most important risk factor for cirrhosis and death in patients with 
4 340:5. 43:6. 47:7.  349: 8. Thomson BJ, Kwong G, Ratib S et al. (2008).  Response rates 
to combination therapy for chronic HCV infection in a clinical setting and derivation of 
probability tables for individual patient management. Journal of Viral Hepatitis; 15: 271-
278
5 Wiese M, Grüngreiff K, Güthoff W, et al (2005). Outcome in a hepatitis C (genotype 
1b) single source outbreak in Germany – a 25 year multicentre study. Journal of 
Hepatology; 43: 590–598.
6 Ferenci P, Ferenci S, Datz C, Rezman I, Oberaigner M, Strauss R (2007). Morbidity and 
mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in 
the 1970s. Journal of Hepatology; 47: 31–36.
7 Poynard T, Bedossa P, Opolon P (1997). Natural history of liver fibrosis progression in 
patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC 
groups. Lancet; 349: 825–832.
8 Thomson BJ, Kwong G, Ratib S et al. (2008).  Response rates to combination therapy 
for chronic HCV infection in a clinical setting and derivation of probability tables for 
individual patient management. Journal of Viral Hepatitis; 15: 271-278.
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chronic HCV or HBV infection9. Conversely, HCV and HBV infection 
increase the risk of cirrhosis in individuals with an alcohol intake 
of >30g/day10. A meta-analysis of 47 studies of the natural history 
of HCV infection in injecting drug users (IDUs) found generally 
poor outcomes in this group, and identified high levels of alcohol 
as a strong predictor of rapid disease progression11. A separate 
study found that alcohol consumption of less than 30g/day does 
not appear to be associated with increased fibrosis in patients with 
chronic HCV infection12. There is also encouraging evidence that 
behavioural programmes in young IDUs with HCV infection can 
lead to significant improvement of alanine transaminase (ALT) in 
those who reduce alcohol consumption13.  
Diabetes
HCV infection has been robustly associated with the development 
9 Bellentani S, Scaglioni F, Ciccia S, Bedogni G, Tribelli C (2011). HCV, HBV and alcohol- 
the Dionysos study. Digestive Diseases; 28: 799-801.
10 Stroffolini T, Cotticelli G, Medda E et al (2010) Interaction of alcohol intake and 
cofactors on the risk of cirrhosis. Liver International; 30: 867-870.
11 John-Baptiste A, Krahn M, Heathcote J, Laporte A, Tomlinson G (2010). The natural 
history of hepatitis C virus infection acquired through injection drug use: meta-analysis 
and meta-regression. Journal of Hepatolology; 53: 245-251.
12 Cheung O, Sterling RK, Salvatori J et al (2011) Mild chronic alcohol consumption is not 
associated with increased fibrosis in patients with chronic hepatitis C. Journal of Clinical 
Gastroenterology; 45: 76-82.
13 Drumright LN, Hagan H, Thomas DL et al (2011) Predictors and effects of alcohol 
use on liver function among young HCV-infected injection drug users in a behavioural 
intervention. Journal of  Hepatology; 55: 45-52.
of insulin resistance and type 2 diabetes mellitus. The insulin resis-
tant state associated with hepatitis C leads to accelerated progres-
sion of liver fibrosis and reduced response to anti-viral therapy14.  
Host genetics
Although demographic and environmental factors have an 
important effect on disease outcomes, they do not fully explain the 
heterogeneity of response, and the host genetic background is 
likely to play a major role. Evidence from twin studies is consistent 
with this concept. A variety of molecular techniques, including 
candidate gene association studies and genome–wide association 
studies have interrogated the relationship between molecular 
variation and diversity of outcome in HBV and HCV infection. 
These studies have found a number of reproducible associations, 
particularly in immune response genes15. The most striking has 
been the identification of a locus within the interleukin (IL) 28-29 
region which appears to have a dominant effect on the outcome of 
treatment for HCV infection. It is likely that IL-28B genotyping will 
become part of routine clinical practice in the foreseeable future. 
Brian J Thomson PhD, FRCP, Associate Clinical Professor, 
University of Nottingham and Nottingham University Hospital
14 Alaei M, Negro F. Hepatitis C virus and glucose and lipid metabolism (2008). Diabetes & 
Metabolism; 34: 692–700.
15 Thurz M, Yee L, Khakoo S (2011). Understanding the host genetics of chronic hepatitis 
B and C. Seminars in Liver Disease; 31: 115-127
Martin Lombard, National Clinical Director for Liver Disease 
outlines some of the issues for the liver strategy, and encourages 
us to get involved by joining the NHS Liver Networks Site. Ed
Liver disease and 
primary care: a briefing 
paper
Patients with liver disease can present in primary care in a number 
of ways and this paper sets out ways in which we would like to 
engage primary care doctors, nurses and other health care workers 
in helping to reduce the prevalence of progressive liver disease and 
to manage the increasing burden on the NHS.
Many doctors in primary 
care are unaware of 
what is happening to the 
relative mortality rate from 
liver disease compared to 
other disease. As shown 
in the graph on the left, 
the death rates from 
cardiovascular disease, 
cancers, respiratory 
disease and strokes are 
decreasing year on year 
since 1970. By contrast 
the red line which is 
rising represents the 
relative mortality from 
liver disease since 1970. 
This is why we need to engage primary care in helping us to tackle 
this important and growing problem.  In addition, the average age of 
death for liver disease is much lower (59 years) than the other main 
causes (72-84 years) and the trends for liver disease in the UK are 
opposite to those in other European countries.
The growth of liver disease:
■	 30% of blood tests from primary care show abnormal liver 
enzymes
■	 >60% of all gastroenterology inpatients are due to liver 
disease
■	 >25% referrals to gastroenterology outpatients are due to 
liver disease
■	 Cirrhosis rates in the UK have more than doubled in the past 
10 years
■	 There are 700 liver transplants a year in the UK, but 700,000 
people with significant liver disease
The principal reasons for the growth in liver disease:
■	 Alcohol: especially resulting in liver disease in 35-65 year 
age groups
■	 Hepatitis C: especially 
in current or former drug 
users, it is potentially a 
curable condition
■	 Hepatitis B: especially in 
immigrant populations, 
its progression can be 
delayed/avoided by 
treatment
■	 Fatty liver disease 
associated with obesity 
and diabetes; becoming 
the most common 
reason for referral and 
fastest growing cause 
for cirrhosis
For more information please join the NHS Liver Networks Site 
by emailing liverstrategy@dh.gsi.gov.uk
Martin Lombard, National Clinical Director for Liver Disease
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Iain Brew takes us through the ways 
in which we can support people going 
through treatment for hepatitis C. Ed
Management 
of hepatitis C 
treatment and 
side effects
Current antiviral treatment for hepatitis 
C consists of weekly subcutaneous 
injections of pegylated interferon alpha, 
which has virucidal activity with daily 
oral ribavirin, which interferes with viral 
replication.  Pegylated interferon has a 
molecule of polyethylene glycol attached, 
which causes the interferon to remain in 
the body for longer. 
Both drugs can produce a number of 
side effects; some are more serious than 
others, but careful monitoring of patients 
is essential during and immediately after 
treatment. Duration of antiviral medication 
is decided on genotype and viral load. 
Genotypes 2 and 3 with low viral load may 
be cleared with as little as twelve weeks 
treatment, but types 1 and 4 require 48 
weeks. 
Interferon
Common side effects mimic other viral 
infections – lethargy, loss of appetite, 
nausea and diarrhoea are particularly likely 
in the first six to eight weeks of treatment. 
Many patients describe symptoms of “flu” 
and may need rest or time off work, but 
supportive and symptomatic treatment is 
usually all that is required. It is perfectly 
reasonable to use paracetamol in hepatitis 
C patients as long as the dose does not 
exceed recommendations and there is 
no evidence of decompensated liver 
cirrhosis. Weight monitoring is important 
and the provision of nutritional support 
should be considered in patients with 
weight loss and doses may need to be 
adjusted if the weight loss is particularly 
bad. 
Treating clinicians will arrange for regular 
blood test monitoring; both interferon and 
ribavirin can cause myelosuppression 
affecting red cell, white cell and platelet 
production. If the neutrophil count is 
consistently below 0.5, granulocyte 
colony stimulating factor (GCSF) may be 
considered and erythropoietin (EPO) may 
be necessary to reverse anaemia in severe 
cases. As with haematological side effects 
in chemotherapy for cancers, treatment 
holidays or dose reductions have been 
used to manage these serious side effects 
effectively, but it is important to maximize 
the chances of sustained viral response 
(SVR) by getting the maximum possible 
dose of treatment into the minimum time. 
Unless a patient presents with fever or 
acute illness, there should be no need for 
further blood testing by other clinicians. 
“ Many patients describe 
symptoms of 
“flu” and may 
need rest or time 
off work, but 
supportive and 
symptomatic 
treatment is 
usually all that is 
required”
Less common adverse effects include 
thyroid disturbances; either hyper- or 
hypothyroid may result. Thyroid function 
is another part of routine monitoring of 
patients whilst in treatment. Although 
patients are often concerned about 
alopecia, this is not common and is rarely 
significant. 
Local reactions at the injection site are 
common: pain, redness and induration 
are effectively managed with 1% 
hydrocortisone cream. It is normal to 
alternate between the left and right side of 
the anterior abdominal wall to reduce the 
chances of these reactions. Hard lumps 
in the subcutaneous tissue may remain 
for several months even after treatment is 
complete. 
Ribavirin
Many of the side effects of ribavirin are 
similar to inteferon, especially flu-like 
symptoms and gastrointestinal effects. 
Chest pain, cough and palpitation may 
also occur, but the management of these 
simply consists of excluding serious 
pathology and offering reassurance to the 
patient. 
Patients with pre-existing heart disease 
or ophthalmological problems should 
be monitored for any deterioration in 
their diseases and should be referred for 
expert assessment in case of concern. 
Such deterioration may lead to antiviral 
treatment being abandoned. 
Psychiatric side effects may include 
depression, poor concentration and 
memory loss, suicidal ideation and 
psychosis. It is important that patients 
with a history of serious mental health 
problems be stabilised before treatment is 
considered. Any prescribed psychotropic 
medication should be at a stable dose and 
patients should be advised to avoid self-
medication with alcohol or drugs of abuse, 
which may further increase the risk of 
psychiatric side effects. All health workers 
who are involved with patients undergoing 
antiviral therapy for hepatitis C should be 
alive to the development of psychiatric 
symptoms and should manage these as 
soon as possible. 
As with interferon, haematological 
monitoring is important. Ribavirin 
may cause haemolytic anaemia and 
thrombocytopenia, although the latter is 
not normally clinically important. It is not 
uncommon to see platelet counts below 
50 and these may worry haematology 
laboratories and primary care clinicians 
alike, but spontaneous bleeding is unlikely 
unless the platelet count is below 10. No 
treatment is needed for mild to moderate 
thrombocytopenia, although the clinician 
in charge of antiviral treatment should 
be made aware. As above, there should 
normally be no need for additional blood 
monitoring in primary care unless there is 
good cause. 
Ribavirin is teratogenic in animals, so 
should be avoided during pregnancy 
and adequate contraception is important 
for both men and women undergoing 
treatment. 
During treatment with ribavirin, patients 
may suffer worsening dental problems, 
glossitis and stomatitis. There should be 
adequate provision for dental care and 
oral hygiene is very important. Glossitis 
and stomatitis respond well to barriers 
such as Vaseline or topical steroids if more 
severe, but any opportunistic candida 
infection should be treated at the same 
time. 
Skin rashes resembling psoriasis or 
eczema should be managed with 
emollients with mild steroids being used 
only where really necessary. Stevens 
Johnson syndrome occurs rarely, but 
needs vigorous treatment.
Iain Brew, GPSI Hepatitis C, Leeds 
Community Health Services NHS Trust
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…continued overleaf
Dear Dr Fixit,
 Jim is a 28 year old a patient of mine who 
has a history of heroin use. I have been 
treating him for the last 4 years at my 
surgery and he is on 60mls methadone. 
He has really reduced his drug use and 
now only uses heroin, which he injects 
twice a month. He recently had a positive 
PCR test for hepatitis C which he says he 
was expecting as he has shared injecting 
equipment. He is very clear that he does 
not want treatment at the moment because 
he has a lot going on in his life as he has 
recently started a new job, has moved into 
his own flat where he lives on his own, and 
has a new circle of non drug using friends 
and is socialising a lot more. He says he 
would like to think about treatment in a 
year’s time. Is there anything I can do in 
the meantime to help him?
Reply by Mark Hallam, CDT & Blood 
Borne Virus Medical Lead in Leeds, St 
Martin’s Health Services
Jim’s request is not unreasonable. He 
obviously understands that treatment 
of his hepatitis C may be challenging 
and that it may be too much for him to 
cope with on top of all the other things 
going on in his life. At the age of 28, he 
is still relatively young. We know that 
treatment is best started when people 
are young, but treatment effectiveness 
starts to diminish from around the age of 
40 and he is a few years short of this1. 
Nonetheless a few issues are raised, 
particularly in terms of harm reduction, 
whether to Jim himself or those he may 
1 Royal College of General Practitioners (2007) 
Guidance for the prevention, testing, treatment 
and management of hepatitis C in primary care 
2007
potentially pass his infection on to. There 
is evidence that interventions in primary 
care can be very effective2. 
“ Not only does fatty liver potentially 
accelerate liver damage, 
but there is also an 
association between 
insulin resistance and 
treatment 
resistance”
The first obvious issue is he continues to 
inject heroin twice per month. Jim clearly 
has some knowledge of the potential for 
spread of infection from sharing injecting 
equipment since he said he was not 
surprised by his positive hepatitis C 
result. Nonetheless it is worth exploring 
this issue further: can he be encouraged 
not to inject? If he cannot stop injecting, 
can he be supported not to share 
equipment? Is he aware that sharing 
of all ‘works’ including spoons, filters 
and water is risky? Is he using a needle 
exchange3,4? 
He should also know that sharing of even 
non-injecting drug use paraphernalia 
can pass on hepatitis infections. Jim isn’t 
disclosing cocaine use, but it is known 
that sharing of equipment such as crack 
pipes and cocaine ‘straws’ can pass on 
infection via the mucous membrane injury 
associated with both these practices3,4,5. 
Another crucial issue is whether he is 
on the right dose of methadone? At 
60mls he is at the bottom end of the 
optimum 60-120ml range6,7. Is he getting 
withdrawal symptoms? He will be unlikely 
to succeed in reducing his heroin use 
2 Wright NMJ and Tompkins CNE (2006)  A review 
of the evidence for the effectiveness of Primary 
Prevention interventions for hepatitis C among 
injecting drug users? Harm Reduction Journal 
2006, 3:27.
3 Health Protection Agency (2009) Shooting Up: 
Infections among injecting drug users in the UK
4 Karmochkine M, Carrat F, Dos Santos O, Cacoub 
P, Raguin G (2006) A case control study of risk 
factors for hepatitis C infection in patients with 
unexplained routes of infection. J Viral Hep 2006; 
13:775-782
5 Royal College of General Practitioners (2004) 
Guidance for Working with Cocaine & Crack Us-
ers in Primary Care
6 Department of Health (2007) Drug Misuse & De-
pendence: UK guidelines on clinical management.
7 Royal College of General Practitioners (2011)  
Guidance for the use of substitute prescribing in 
treatment of opioid dependence in primary care 
2011.
and stopping injecting if he continues to 
suffer even very mild withdrawal. 
We also need to ensure he is protected 
from hepatitis A and B which could 
potentially be much worse, if caught on 
top of hepatitis C. Hepatitis A and B are 
preventable and it is essential that Jim is 
offered vaccination for both as soon as 
possible 8,9,10.
There are a few other factors which 
can potentially be modified, to limit the 
damage of chronic hepatitis C to Jim’s 
liver. Is he using alcohol? It is clear that 
alcohol use even in relatively modest 
amounts is undesirable for two reasons: 
first there is a danger of accelerating 
the progression of liver fibrosis towards 
cirrhosis; second it is known that alcohol 
reduces the effectiveness of hepatitis 
C treatment
1
. Jim should be advised 
that total abstinence from alcohol is the 
safest option. Failing that, he should be 
advised to limit consumption to as little as 
possible and well below the standard 21 
units per week recommended as the limit 
for a (healthy) man11. 
If Jim is a higher risk drinker, every ef-
fort should be made to motivate him to 
address the issue before he reaches 
the point where he starts on any future 
treatment for his hepatitis C. It is worth 
noting that smoking can also accelerate 
progression of hepatitis C1,12. 
Another important factor which can also 
potentially be modified is weight. Hepatic 
steatosis (fatty liver) is increasingly rec-
ognised as being an important cause of 
liver disease. It is often (but not always) 
associated with obesity. If Jim has a body 
mass index of over 29, efforts should be 
made to encourage him to lose weight 
through a program of healthy eating and 
exercise. Not only does fatty liver poten-
tially accelerate liver damage, but there 
8 Department of Health (2011)  Immunisation 
against infectious disease: “the Green Book”:  
Update 
9 Vento S, Garofano T, Renzini C, et al. (1998) Ful-
minant hepatitis associated with hepatitis A virus 
superinfection in patients with chronic hepatitis C. 
N Engl J Med 1998; 338(5):286–90.
10 Sundkvist T, et al (2003) Outbreak of hepatitis A 
infection among intravenous drug users in Suf-
folk and suspected risk factors. Communicable 
Disease and Public Health, 2003. 6(2): p. 101–5.
11 Hutchinson SJ, Bird SM, Goldberg DJ. (2005) In-
fluence of alcohol on the progression of hepatitis 
C virus infection: a meta-analysis. Clinical Gastro-
enterology & Hepatology. 2005 Nov; 3(11):1150–9
12 Hezode C, Lonjon I, Roudot-Thoraval F, et al 
(2003) Impact of smoking on histological liver le-
sions in chronic hepatitis C. Gut 2003;52(1):126–
9
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Dear Dr Fixit
Shaun is a 49 year old patient who has 
been in drug treatment at my surgery for 
7 years. During this time he has ceased 
all illicit drug use. However over the past 
2 years his alcohol use has increased 
and he is now drinking 3 cans of strong 
lager a day, he says to cope with boredom 
and to cheer him up. He lives alone, but 
has regular contact with his son and 
daughter who are in their 20’s. He has 
also steadily put on weight whilst he has 
been in treatment and now has a BMI of 
34. He smokes ½ ounce of tobacco a day. 
He has recently tested PCR positive for 
hepatitis C and wants to start treatment 
but I have heard that people drinking this 
much don’t get accepted for treatment 
programmes. How can I help him?
Answer provided by Steve Brinksman, 
Clinical Director SMMGP
When teaching medical students and GP 
registrars at Fixit Health Centre I make a 
point of stressing to them early on that 
a basic issue in primary care is to learn 
to deal with uncertainty and at the same 
time to be aware of the fundamental 
interconnectedness of all things1. 
Shaun presents with multiple possible 
pathologies that can interact with each 
other to potentiate the level of morbidity 
that occurs. Like Dirk Gently we must 
learn to take a holistic approach in which 
our relationship with the patient is equally 
as vital as our diagnostic acumen and our 
prescription pad. Whilst acknowledging 
the importance of understanding the 
disease processes involved we must also 
1   Douglas Adams: Dirk Gently’s Holistic Detective 
Agency
is also an association between insulin 
resistance and treatment resistance13,14. 
It is important that Jim doesn’t pass his 
infection on. Aside from activities as-
sociated with his drug use, there are a 
number of ways this can happen. The 
common denominator is blood. Although 
the hepatitis C virus can be identified 
in various bodily fluids, blood is pretty 
much the only medium when it comes to 
spread of infection
1,15
. Thus, it is impor-
tant to reassure him that normal person to 
person contact, including such as hug-
ging or kissing, cannot pass on hepatitis 
C. The activities which he needs to be 
concerned about involve inoculation of 
blood.   Even in minute amounts, blood 
passing from an infected to the blood-
stream of an uninfected person, carries 
risk of transmitting the infection
1, 4, 16
. 
There is some risk of an exchange of 
blood occurring through sharing of items 
such as toothbrushes and razor blades. 
Many suffer from mild gum disease and if 
two such share a toothbrush, minute de-
posits of blood may be picked up on the 
bristles and inoculated into the bleeding 
surfaces of the gums of another. It is not 
difficult to imagine how this may occur 
with razor blades – but similarly nail clip-
pers also may be a source of risk
1
. 
You mention Jim lives alone; people may 
come to stay or he may embark on a re-
lationship where inadvertent sharing of 
such implements may take place and he 
should be advised on the risks. The issue 
of sexual risk needs to be covered, even 
if Jim has no partner at the moment. Be-
cause minute amounts of blood can be 
exchanged during sex there is some risk 
of transmission of hepatitis C. However, 
evidence suggests that the risk associ-
ated with ‘non-rough’ heterosexual sex is 
low. One study of nearly 900 heterosexu-
al monogamous couples failed to find a 
single case of intra-spousal transmission 
and other sources have quoted life-time 
risk for same type of couple as 2-3%1,16. 
13 Hu KQ, Kyulo NL, Esrailian E, et al. (2004) 
Overweight and obesity, hepatic steatosis and 
progression of chronic hepatitis C: a retrospective 
study on a large cohort of patients in the United 
States. J Hepatol 2004; 40(1): 147– 54
14 Bressler B, Guindi M, Tomlinson G, et al. (2003) 
High body mass index is an independent risk 
factor for non response to antiviral treatment in 
chronic hepatitis C. Hepatology 2003; 38:639-44 
15 World Health Organization Hepatitis C fact sheet 
No 164 June 2011
16 Vandelli C, et al. Am J Gastro (2004) Lack of 
Evidence of Sexual Transmission of Hepatitis C 
among Monogamous Couples: Results of a 10-
Year Prospective Follow-Up Study.; 99: 855-859.
There is higher risk with ‘rough’ sex, sex 
with multiple partners – or with men hav-
ing sex with men. In all these scenarios 
use of condoms considerably diminishes 
risks of transmission of infection. 
It is worth returning to the issue of why 
Jim is choosing to delay his treatment. As 
already mentioned, his reasoning may be 
sound. With his age being somewhat less 
than 40 and a presumed relatively short 
history of hepatitis C, it is unlikely that 
delay of a year would result in significant 
worsening of either his condition or of his 
chances of successful treatment. 
It is worth considering other issues which 
may influence his decision to delay. Jim 
may believe he cannot be referred for 
treatment because he continues to inject 
heroin. NICE guidance is now in favour of 
offering hepatitis C treatment to people 
who are still injecting (NB not all hepa-
tology departments will have adopted 
this principle, but should be challenged 
if they have not) 1,17. Some additional 
blood tests could also help him reach a 
decision. Knowing his genotype would 
be helpful to give him an idea of the suc-
cess rates of treatment, and knowing a 
bit more about the state of his liver could 
also be helpful. If there was any sign of 
damage to his liver I would advise him to 
go for early treatment.
Jim may fear having a liver biopsy as part 
of assessment for treatment of his hepa-
titis C. It is worth pointing out that most 
people don’t need a liver biopsy before 
treatment, especially if they are young, 
have genotype 2 or 3 have no liver dam-
age, no significant history of problematic 
alcohol use and a less complex history 
(and the advent of ‘Fibroscan’ tests may 
reduce the need to carry out diagnostic 
liver biopsy still further).
Finally Jim may have misconceptions 
about hepatitis C treatment and you can 
really help here and explain the main 
side-effects, explain he will be supported 
through treatment by a specialist hepatol-
ogy nurse and that he can talk to some-
one who has been through treatment. He 
could be put in contact with an organisa-
tion such as the Hepatitis C Trust or a lo-
cal support network to address particular 
anxieties and misconceptions he may 
have – about any aspects of the disease 
or its treatment. 
17 National Institute for Clinical Excellence Guidance 
on Hepatitis C, peginterferon alfa & ribavirin – see 
references TA 75, 106 & 200.
Dr Fixit on alcohol, 
obesity and 
hepatitis C
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provide information and psycho-social 
support to try and effect behavioural 
change2.
Faced with the three commonest causes 
of cirrhosis the outlook for Shaun’s liver 
would appear bleak. However there is 
evidence that two of these problems, 
alcohol and obesity, can be resolved 
or at least be significantly ameliorated 
by behavioural change and the third, 
hepatitis C, is potentially treatable by 
medical intervention.3 
The fact that Shaun is keen to get into 
a treatment programme suggests he is 
aware of some of the issues surrounding 
chronic viral hepatitis and that he has 
some motivation to change. This may 
well provide the impetus to promote other 
changes. It will be important to assess 
any underlying liver damage but I would 
not wait for the results of investigations 
before trying to engage him in making 
the significant alterations necessary in 
his life. I find that referring to significant 
weight loss and reductions or preferably 
abstention from alcohol can be difficult 
and you may need outside help if you 
have it available. The focus should be 
on the fact that there are treatments for 
these conditions which have been shown 
to have significant results.
Arrange LFTs and also send him for 
an ultrasound scan of his liver. Viral 
hepatitis, alcoholic and non-alcoholic 
fatty liver disease (sometimes referred to 
as steatosis) can all produce abnormal 
LFTs. However very high levels would be 
best managed with an urgent hepatology 
assessment. The ultrasound scan may 
show evidence of fatty change within 
the liver and if associated with abnormal 
LFTs referral for liver biopsy or if available 
a fibroscan should be considered. 
Trying to maintain a holistic approach 
we should remain aware of other 
possible non-hepatic problems. Non-
Alcoholic Fatty Liver Disease is one of 
the components of metabolic syndrome 
so the possibility exists that he may 
have associated co-morbidities such 
as hypertension, hyperlipidaemia and 
impaired glucose tolerance or even type 
2 diabetes. Should any of these problems 
co-exist then they should be treated and 
2   Miller W, Rollnick S (2002). Motivational interview-
ing; preparing people for change. Second edition. 
New York:Guilford Press
3   National Institute for Health and Clinical Excel-
lence CE TA75 Hepatitis C pegylated interferons, 
ribavirin and alfa interferon: guidance
there is some evidence that statins may 
reduce the hepatic risk in NAFLD as well 
as the cardiovascular risk. 
Shaun has already mentioned that his 
alcohol consumption is linked to boredom 
and to “cheer him up” and there is a 
large overlap between common mental 
health problems such as depression and 
anxiety and excess alcohol and drug 
use. Clinical judgement and a validated 
screening questionnaire should be used 
to assess if this may be true for Shaun. 
If so then treatment for his mental health 
may help him reduce or stop his alcohol. 
Referral to mutual aid groups and local 
day services may also help him reduce 
his boredom and improve his mood and 
motivation.
“ you can give practical advice 
such as reducing the 
strength of alcohol he 
is consuming”
Hepatitis C treatment should no longer 
be denied to patients purely because 
they are in opiate substitution treatment 
and increasingly evidence suggests that 
even those continuing to use illicit drugs 
may benefit from treatment. However 
it is well established that not only does 
excess alcohol hasten the progression of 
the disease but it also adversely interferes 
with treatment, an effect exacerbated 
by both obesity and cigarette smoking, 
and for this reason some services may 
decline treatment until he has reduced 
or stopped his alcohol use. Shaun 
is also older and male both of which 
reduce the chance of treatment success, 
highlighting the need for him to make as 
much positive change as possible.
With Shaun drinking over 100 units a 
week, he probably has a degree of 
physical dependence and so may need 
a community or in-patient detox. If he 
is not motivated to take this step, brief 
interventions have been shown to be 
effective4 and as part of this you can 
give practical advice such as reducing 
the strength of alcohol he is consuming 
such as reducing from 9.8% ABV lager 
to 5.6% ABV. This will reduce his units 
by over a third even if he continues to 
drink 3 cans a day. If he manages this, 
4   Dunn C, Deroo L, Rivara F (2001). The use of brief 
interventions adapted from motivational interviewing 
across behavioural domains; a systematic review. 
Addiction;96:1725-1742
then set him another goal for example 
to reduce his weekly units to under 50. 
Work with him at each stage, encourage 
him and celebrate that he is a step nearer 
to treatment. Keep working with him and 
if available get support from an alcohol 
counsellor or project.
Shaun should also be encouraged to lose 
weight and as he lives alone he may need 
help and advice on preparing healthy 
lower calorie meals as well as increasing 
his exercise. Before recommending a 
significant increase in exercise it would 
be a sensible precaution to assess his 
risk of cardiovascular disease. Regular 
review around weight loss is effective 
and when coupled with peer support is 
one of the reasons that weight watchers 
and similar groups can be successful. 
There would also be benefit from smoking 
cessation. 
Most of us find so much change at one 
time daunting and may choose to make 
smaller changes or concentrate on 
one area at a time. This approach may 
give the confidence to later effect other 
changes and in the absence of evidence 
of significant liver disease then I feel it 
should be agreed with him as to the order 
in which these are tackled. 
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COURSES AND EVENTS
RCGP Certificate in the Detection, 
Diagnosis and Management of Hepatitis B 
and C in Primary Care
Thursday 24th November – Manchester
To book on a training day visit the RCGP Substance Misuse Unit at
http://www.rcgp.org.uk/substance_misuse.aspx  
or email hepbandc@rcgp.org.uk
A two hour emodule  is freely available at  
http://elearning.rcgp.org.uk and can be done as a standalone or in 
preparation for the Part 1 Training Day.
RCGP Certificate Reducing Harm, 
Maximising Health, Recovery and 
Wellbeing for People using Drugs and 
Alcohol
17th November London
Bookings can be made online at 
http://www.rcgp.org.uk/substance_misuse.aspx 
Or contact the Programme Coordinator, Marianne Thompson at 
reducingharm@rcgp.org.uk or 020 3188 7653
A two hour emodule  is freely available at 
http://elearning.rcgp.org.uk and can be done as a standalone or in 
preparation for the Part 1 Training Day.
For more information contact llea@rcgp.org.uk
